Spesolimab

Specification

• Cat#: THA-0133
• Product Name: Spesolimab
• Description: Spesolimab is an interleukin-36 receptor antagonist used to treat generalized pustular psoriasis flares in adults.
• Sequences: Not Available
• Molecular Weight: 146000.0 Da (approximate)
• Introduction: Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares. Spesolimab works by inhibiting the inflammatory signaling pathway of IL-36, which is often overexpressed and aberrantly overactive in generalized pustular psoriasis. Spesolimab received recommendations from the EMA's Committee for Medicinal Products for Human Use (CHMP) to be granted marketing authorization in October 2022 and was finally approved in December 2022 for the treatment of flares in adult patients with generalized pustular psoriasis.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C6480H9988N1736O2012S46
• Appearance: Liquid

Pharmaceutical Information

• Pharmacodynamics: Spesolimab works to reduce inflammation in GPP in a rapid and sustained manner by blocking inflammatory pathways. In clinical trials, spesolimab reduced pustules and improved other disease measures in patients with GPP, irrespective of IL36RN gene mutation status.
• Targets: Interleukin-1 receptor-like 2